13 / 30
Nanobiotechnology 2018
Page 53
Nano Research & Applications
ISSN: 2471-9838
E u r o S c i C o n C o n f e r e n c e o n
Nanotech & Nanobiotechnology
J u l y 1 2 - 1 3 , 2 0 1 8
P a r i s , F r a n c e
T
wo fundamental and unsolved problems facing bioimaging and nanomedicine are nonspecifc uptake of intravenously
administered diagnostic and/or therapeutic agents by normal tissues and organs, and incomplete elimination of unbound
targeted agents from the body. To solve these problems, we have synthesized a series of indocyanine near-infrared (NIR)
fluorophores that varied systematically in net charge, conformational shape, hydrophilicity/lipophilicity, and charge distribution.
Using 3D molecular modelling and optical fluorescence imaging, we have defned the relationship among the key independent
variables that dictate biodistribution and tissue-specifc targeting such as lung and sentinel lymph nodes, human prostate cancers
and human melanomas. Recently, we have developed new pharmacophore design strategy structure-inherent targeting, where
tissue- and/or organ-specifc targeting is engineered directly into the non-resonant structure of a NIR fluorophore, thus creating
the most compact possible optical contrast agent for bioimaging and nanomedicine. The biodistribution and targeting of these
compounds vary with dependence on their unique physicochemical descriptors and cellular receptors, which permit 1) selective
binding to the target tissue/organ, 2) visualization of the target specifcally and selectively, and 3) provide curing options such
as image-guided surgery or photo dynamic therapy. Our study solves two fundamental problems associated with fluorescence
image-guided surgery and lays the foundation for additional targeted agents with optimal optical and
in vivo
performance.
hchoi12@mgh.harvard.eduBioimaging and nanomedicine for cancer
theranostics
Hak Soo Choi
Harvard Medical School, USA
Dana-Farber/Harvard Cancer Center, USA
Nano Res Appl 2018, Volume 4
DOI: 10.21767/2471-9838-C2-012